Study Overview: This research is for people with a type of pancreatic cancer called metastatic pancreatic ductal adenocarcinoma (PDAC). The study looks at how well regular chemotherapy works with or without a special drug named INCB161734.

Eligibility: To join, participants need a confirmed diagnosis of PDAC with a specific gene change called KRAS G12D mutation. This means the cancer has this exact genetic change. You shouldn't have had any treatment before for metastatic cancer. You must be in good enough health to handle treatment, which is assessed by a system called ECOG Performance Status. This measures how well you can carry out daily activities.

Key Points:

• Study Duration: Participation involves multiple visits, but the length isn't specified.
• Compensation: The document does not mention compensation details.
• Risks: There may be risks associated with chemotherapy and the new drug, but they are not detailed here.